The opposite effect of tapinarof between IMQ and IL-23 induced psoriasis mouse models.
imiquimod
interleukin-23
psoriasis
tapinarof
Journal
Experimental dermatology
ISSN: 1600-0625
Titre abrégé: Exp Dermatol
Pays: Denmark
ID NLM: 9301549
Informations de publication
Date de publication:
23 Jun 2023
23 Jun 2023
Historique:
revised:
06
06
2023
received:
20
02
2023
accepted:
09
06
2023
medline:
23
6
2023
pubmed:
23
6
2023
entrez:
23
6
2023
Statut:
aheadofprint
Résumé
Tapinarof is an aryl hydrocarbon receptor (AHR) ligand which is used to treat plaque psoriasis in adults. However, the underlying mechanism is not yet fully understood. In this study, we applied two of the most studied psoriasis mouse models: topical application of imiquimod (IMQ) and subcutaneous injection of IL-23. Although both models successfully induced psoriasis-like lesions in mice, tapinarof had a completely opposite effect on the two models. Tapinarof decreased the expression of multiple essential cytokines involved in the pathological IL-23/IL-17/IL-22 axis and ameliorated IMQ-induced psoriatic dermatitis, inhibiting keratinocyte proliferation and abnormal differentiation. However, in the IL-23-injection-model, tapinarof instead aggravated the disease. Here, tapinarof increased epidermal thickness and differentiated epidermal dysplasia in mice. Our data suggest that tapinarof may have different effects on varied types of psoriasis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : CAMS Innovation Fund for Medical Science
ID : 2019-I2M-5-066
Organisme : National Natural Science Foundation of China
ID : 81703097
Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Nair PA, Badri T. Psoriasis. StatPearls Publishing LLC; 2022.
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301-1315. doi:10.1016/s0140-6736(20)32549-6
Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med. 2004;199(1):125-130. doi:10.1084/jem.20030451
Shou Y, Yang L, Yang Y, Xu J. Inhibition of keratinocyte ferroptosis suppresses psoriatic inflammation. Cell Death Dis. 2021;12(11):1009. doi:10.1038/s41419-021-04284-5
Hoegler KM, John AM, Handler MZ, Schwartz RA. Generalized pustular psoriasis: a review and update on treatment. J Eur Acad Dermatol Venereol. 2018;32(10):1645-1651. doi:10.1111/jdv.14949
Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol. 2021;84(4):1059-1067. doi:10.1016/j.jaad.2020.10.085
Bissonnette R, Bolduc C, Maari C, et al. Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol. 2012;26(12):1516-1521. doi:10.1111/j.1468-3083.2011.04332.x
Cai L, Chen GH, Lu QJ, et al. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis. Chin Med J (Engl). 2020;133(24):2905-2909. doi:10.1097/cm9.0000000000001221
Singh TP, Zhang HH, Hwang ST, Farber JM. IL-23- and Imiquimod-induced models of experimental psoriasis in mice. Curr Protoc Immunol. 2019;125(1):e71. doi:10.1002/cpim.71
Di Meglio P, Duarte JH, Ahlfors H, et al. Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity. 2014;40(6):989-1001. doi:10.1016/j.immuni.2014.04.019
Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137(10):2110-2119. doi:10.1016/j.jid.2017.05.004
Tortola L, Rosenwald E, Abel B, et al. Psoriasiform dermatitis is driven by IL-36-mediated DC-keratinocyte crosstalk. J Clin Invest. 2012;122(11):3965-3976. doi:10.1172/jci63451
Jean J, Soucy J, Pouliot R. Effects of retinoic acid on keratinocyte proliferation and differentiation in a psoriatic skin model. Tissue Eng Part A. 2011;17(13-14):1859-1868. doi:10.1089/ten.TEA.2010.0463
Wu J, Li S, Li T, et al. pDC activation by TLR7/8 ligand CL097 compared to TLR7 ligand IMQ or TLR9 ligand CpG. J Immunol Res. 2019;2019:1749803. doi:10.1155/2019/1749803
van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009;182(9):5836-5845. doi:10.4049/jimmunol.0802999
Flutter B, Nestle FO. TLRs to cytokines: mechanistic insights from the imiquimod mouse model of psoriasis. Eur J Immunol. 2013;43(12):3138-3146. doi:10.1002/eji.201343801
Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203(12):2577-2587. doi:10.1084/jem.20060244
Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol. 2021;17(8):835-852. doi:10.1080/1744666x.2021.1940962
Zhu X, Jiang L, Zhong Q, et al. Abnormal expression of interleukin-6 is associated with epidermal alternations in localized scleroderma. Clin Rheumatol. 2022;41(7):2179-2187. doi:10.1007/s10067-022-06127-w
Hawkes JE, Yan BY, Chan TC, Krueger JG. Discovery of the IL-23/IL-17 signaling pathway and the treatment of psoriasis. J Immunol. 2018;201(6):1605-1613. doi:10.4049/jimmunol.1800013
Zhu H, Lou F, Yin Q, et al. RIG-I antiviral signaling drives interleukin-23 production and psoriasis-like skin disease. EMBO Mol Med. 2017;9(5):589-604. doi:10.15252/emmm.201607027
Ando N, Nakamura Y, Aoki R, et al. Circadian gene clock regulates psoriasis-like skin inflammation in mice. J Invest Dermatol. 2015;135(12):3001-3008. doi:10.1038/jid.2015.316
Takemura M, Nakahara T, Hashimoto-Hachiya A, Furue M, Tsuji G. Glyteer, soybean tar, impairs IL-4/Stat6 signaling in murine bone marrow-derived dendritic cells: the basis of its therapeutic effect on atopic dermatitis. Int J Mol Sci. 2018;19(4):1169. doi:10.3390/ijms19041169
Quintana FJ, Murugaiyan G, Farez MF, et al. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2010;107(48):20768-20773. doi:10.1073/pnas.1009201107
Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature. 2008;453(7191):106-109. doi:10.1038/nature06881
Haarmann-Stemmann T, Esser C, Krutmann J. The Janus-faced role of aryl hydrocarbon receptor signaling in the skin: consequences for prevention and treatment of skin disorders. J Invest Dermatol. 2015;135(11):2572-2576. doi:10.1038/jid.2015.285
Chen H, Zhao Q, Zhong Q, et al. Skin microbiome, metabolome and skin phenome, from the perspectives of skin as an ecosystem. Phenomics. 2022;2(6):363-382. doi:10.1007/s43657-022-00073-y
Cussotto S, Strain CR, Fouhy F, et al. Differential effects of psychotropic drugs on microbiome composition and gastrointestinal function. Psychopharmacology. 2019;236(5):1671-1685. doi:10.1007/s00213-018-5006-5
Shinno-Hashimoto H, Hashimoto Y, Wei Y, et al. Abnormal composition of microbiota in the gut and skin of imiquimod-treated mice. Sci Rep. 2021;11:11265. doi:10.1038/s41598-021-90480-4
Zanvit P, Konkel JE, Jiao X, et al. Antibiotics in neonatal life increase murine susceptibility to experimental psoriasis. Nat Commun. 2015;6:8424. doi:10.1038/ncomms9424